Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.